FIRST EXTENSION - GRANTED
granted
on 12 Jun 2024
Last Applicant/ Owned by
35 North Lake Avenue, Suite 710
Pasadena
CA
91101
Serial Number
97600809 filed on 21st Sep 2022
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
PAPILLON BIOSCIENCES
Development of nanotechnology-based pharmaceutical preparations for cancer delivery platforms; research and development of pharmaceuticals for the treatment of cancer; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines Pharmaceutical and medicinal preparations for the treatment of cancer; vaccines for human use
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Development of nanotechnology-based pharmaceutical preparations for cancer delivery platforms; research and development of pharmaceuticals for the treatment of cancer; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical and medicinal preparations for the treatment of cancer; vaccines for human use
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97600809
Mark Type
No Service Mark
Attorney Docket Number
No 348347-NEW
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 12th Jun 2024 | SOU EXTENSION 1 FILED |
| 12th Jun 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 12th Jun 2024 | SOU EXTENSION 1 GRANTED |
| 12th Jun 2024 | SOU TEAS EXTENSION RECEIVED |
| 19th Dec 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 24th Oct 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 24th Oct 2023 | PUBLISHED FOR OPPOSITION |
| 04th Oct 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 16th Sep 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 15th Sep 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |